These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 18372513)
1. [Molecular targeting therapy for gynecologic cancer]. Hatae M; Nakamura T; Onishi Y; Yamamoto F Gan To Kagaku Ryoho; 2008 Feb; 35(2):233-237. PubMed ID: 18372513 [No Abstract] [Full Text] [Related]
2. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Roy V; Perez EA Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790 [TBL] [Abstract][Full Text] [Related]
3. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Wallerand H; Reiter RR; Ravaud A Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279 [TBL] [Abstract][Full Text] [Related]
4. Modelling and simulation of chemotherapy of haematological and gynaecological cancers. Nani FK; Oğuztöreli MN IMA J Math Appl Med Biol; 1999 Mar; 16(1):39-91. PubMed ID: 10335600 [TBL] [Abstract][Full Text] [Related]
5. The mechanism of action of plitidepsin. Muñoz-Alonso MJ; González-Santiago L; Martínez T; Losada A; Galmarini CM; Muñoz A Curr Opin Investig Drugs; 2009 Jun; 10(6):536-42. PubMed ID: 19513942 [TBL] [Abstract][Full Text] [Related]
6. Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: a call for greater objectivity. Markman M Gynecol Oncol; 2006 Sep; 102(3):419-20. PubMed ID: 16814850 [No Abstract] [Full Text] [Related]
7. [New perspectives in cancer treatment]. Brugarolas A; Giráldez J Rev Med Univ Navarra; 1998; 42(3):127-33. PubMed ID: 10420935 [No Abstract] [Full Text] [Related]
8. Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer. Köchli OR; Sevin BU; Averette HE; Haller U Contrib Gynecol Obstet; 1994; 19():12-23. PubMed ID: 7995043 [No Abstract] [Full Text] [Related]
9. Targeting angiogenesis in gynecologic cancers. Zand B; Coleman RL; Sood AK Hematol Oncol Clin North Am; 2012 Jun; 26(3):543-63, viii. PubMed ID: 22520979 [TBL] [Abstract][Full Text] [Related]
13. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Roukos DH; Tzakos A; Zografos G Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000 [No Abstract] [Full Text] [Related]
14. Combination chemotherapy in clinical practice: recent applications to gynecologic cancers. Wade ME; Williams HM Conn Med; 1967 Jun; 30(6):426-9. PubMed ID: 6046075 [No Abstract] [Full Text] [Related]
15. [Changes in the karyotype of leukocytes cultivated in peripheral blood of gynecologic cancer patients under antineoplastic chemotherapy]. Curcio S Arch Ostet Ginecol; 1972; 77(5):352-60. PubMed ID: 4681172 [No Abstract] [Full Text] [Related]
16. [Changes of lactic acid isoenzyme (LDH5) in the serum during the cytostatic treatment of gynecologic cancer]. Skoda V; Trnková M; Skramovský V; Jandová A; Novotná J Cesk Gynekol; 1967 Feb; 32(1):14-7. PubMed ID: 6044942 [No Abstract] [Full Text] [Related]
17. [Chemotherapy in the gynecologic oncology]. Minerva Med; 1971 Apr; 62(28):1474-5. PubMed ID: 5567640 [No Abstract] [Full Text] [Related]
18. [Supportive measures for cytostatic therapy of gynecologic cancers]. Sevelda P; Vavra N; Barrada M; Seifert M; Wagner T; Salzer H Gynakol Rundsch; 1991; 31 Suppl 2():21-5. PubMed ID: 1724225 [No Abstract] [Full Text] [Related]
19. New molecular targets for anticancer therapy. The First International Conference on New Molecular Targets for Anticancer Therapy. Naples, Italy. June 22-23 1998. Normanno N; Agrawal S Mol Med Today; 1998 Dec; 4(12):514-6. PubMed ID: 9866820 [No Abstract] [Full Text] [Related]
20. [A model for gynecologic tumor therapy]. Brody S; Gemzell C Lakartidningen; 1969 Jul; 66(27):2751-4. PubMed ID: 5804633 [No Abstract] [Full Text] [Related] [Next] [New Search]